Status:
UNKNOWN
A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Conditions:
Predictive Cancer Model
Pancreas Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Importance: Lymphovascular invasion (LVI) is a poor prognosis pathologic feature in pancreatic ductal adenocarcinoma (PDAC) patients. Neoadjuvant therapy may bring survival benefits to these patients....
Eligibility Criteria
Inclusion
- Patients who were pathologically diagnosed as PDAC and received curative surgery.
Exclusion
- Patients with distant metastasis; Patients who received neoadjuvant therapy; Patients with a survival time of less than 1 month.
Key Trial Info
Start Date :
May 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2023
Estimated Enrollment :
1009 Patients enrolled
Trial Details
Trial ID
NCT05997147
Start Date
May 1 2023
End Date
August 30 2023
Last Update
August 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300060